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Background: Despite the evidence showing the promise of HIV treatment as prevention (TasP) in reducing HIV
incidence, a variety of ethical questions surrounding the implementation and “scaling up” of TasP have been
articulated by a variety of stakeholders including scientists, community activists and government officials. Given the
high profile and potential promise of TasP in combatting the global HIV epidemic, an explicit and transparent
research priority-setting process is critical to inform ongoing ethical discussions pertaining to TasP.
Methods: We drew on the Arksey and O’Malley framework for conducting scoping review studies as well as
systematic approaches to identifying empirical and theoretical gaps within ethical discussions pertaining to
population-level intervention implementation and scale up. We searched the health science database PubMed to
identify relevant peer-reviewed articles on ethical and implementation issues pertaining to TasP. We included English
language articles that were published after 2009 (i.e., after the emergence of causal evidence within this field) by using
search terms related to TasP. Given the tendency for much of the criticism and support of TasP to occur outside the
peer-reviewed literature, we also included grey literature in order to provide a more exhaustive representation of
how the ethical discussions pertaining to TasP have and are currently taking place. To identify the grey literature, we
systematically searched a set of search engines, databases, and related webpages for keywords pertaining to TasP.
Results: Three dominant themes emerged in our analysis with respect to the ethical questions pertaining to TasP
implementation and scale-up: (a) balancing individual- and population-level interests; (b) power relations within
clinical practice and competing resource demands within health care systems; (c) effectiveness considerations and
socio-structural contexts of HIV treatment experiences within broader implementation contexts.
Conclusion: Ongoing research and normative deliberation is required in order to successfully and ethically scale-up
TasP within the continuum of HIV care models. Based on the results of this scoping review, we identify several ethical
and implementation dimensions that hold promise for informing the process of scaling up TasP and that could benefit
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The role of antiretroviral therapy (ART) in preventing
the onward spread of HIV is now widely accepted as a
crucial component within comprehensive HIV preven-
tion efforts [1] based on a variety of empirical findings,
including those stemming from mathematical modeling
[2], population-level surveillance studies [3,4] and clin-
ical trials [5]. Thus, ‘treatment as prevention’ (TasP) has
been positioned as a ‘double-hat trick’ [6] based on ART’s
role in preventing disease progression among HIV-
positive individuals, as well as population-level benefits of
decreasing community-level viral loads and the likelihood
of onward transmission to uninfected partners [3,7]. Des-
pite the evidence showing the promise of TasP in reducing
HIV incidence, scientists, community activists and gov-
ernment officials have raised ethical questions regarding
the implementation and scaling-up of TasP. To date, how-
ever, the scope of these discussions in the literature has
remained largely unexamined [8], with the exception of a
recent systematic review of a particular set of ethical is-
sues associated with clinical and health service challenges
related to the HIV “test and treat” strategies [9].
Given the high profile and potential promise of TasP in
combatting the global HIV epidemic, an explicit and trans-
parent research priority-setting process is critical to mean-
ingfully inform ongoing ethical discussions pertaining to
TasP. This strategy requires a comprehensive and system-
atic synthesis of the key ethical issues and concerns related
to the implementation and scaling up TasP as expressed by
both scientists and community stakeholders. For example,
within the TasP approach, clinical treatment guidelines
within many settings now recommend ART for all individ-
uals living with HIV, regardless of their individual CD4
count or based on an expanded set of parametersa. This
raises questions about the kinds of efforts that will be re-
quired within these large-scale programs to identify and
engage HIV positive individuals into long-term care and
treatment. As a result, questions related to an individual’s
autonomy and the potential for coercive seeking and test-
ing strategies during implementation warrant examination
[9]. Moreover, there has been increasing concern that
these efforts are being advanced for the benefit of future
populations, rather than for the benefit of individuals who
are currently HIV seropositive [9]. Despite criticisms that
there is insufficient existing scientific evidence to substan-
tiate the trend towards ‘early’ initiation of ART based on
individual-level benefits and/or burdens, recent evidence
from an ongoing clinical trial (HPTN 052) points to a set
of individual-level benefits to early uptake of ART, such as
delayed time to onset of AIDS and decreased incidence of
primary and secondary infections [10]. Nonetheless, there
are increasing calls for more evidence in order to better
understand these and other issues pertaining to the ethical
implementation and scale up of TasP, as well as the broadersocial and structural forces that shape individual experi-
ences of TasP [11].
In this paper, we draw on concepts and approaches
from the field of population and public health ethics to
critically interrogate TasP approaches in order to more
fully consider and negotiate a balance of individual and
collective interests and health outcomes [12]. Our aim is
to provide strategic direction in this field by systematic-
ally identifying and highlighting key ethical questions
pertaining to implementation and scale-up of TasP that
will benefit from new empirical research and theoretical
advances.
Methods
Search strategy and results
We drew on the Arksey and O’Malley framework for
conducting scoping review studies [13,14] as well as sys-
tematic approaches to identifying empirical and theoretical
gaps within ethical discussions pertaining to population-
level intervention implementation and scale up [15]. We
searched the health science database PubMed to identify
relevant peer-reviewed articles on ethical and implementa-
tion issues pertaining to TasP. We included English lan-
guage articles that were published after 2009 (i.e., after the
emergence of causal evidence within this field) by using the
following search terms: HIV, HIV infections, treatment as
prevention, TasP, HIV prevention, and ethics. We included
review articles, and used citation tracking to identify other
relevant sources. We included only articles that included a
discussion of the ethical issues pertaining to the implemen-
tation and/or scaling up of TasP. Articles that only dis-
cussed issues pertaining to TasP research (e.g., ethical issues
that arise in randomized controlled trials) were excluded,
as well as articles that focused exclusively on other HIV
prophylaxis regimes (e.g., PreP). Empirical studies that did
not engage with implementation/scale up or ethical issues
were excluded.
Searches yielded 374 results in PubMed. We reviewed
all abstracts for content, removed duplicates, and in-
cluded those articles related to the ethical and imple-
mentation issues related to TasP, resulting in a total of
19 articles. We also hand searched the references of rele-
vant articles and special journal issues within this field,
and co-authors searched their own library archives,
resulting in additional articles, for a total of 8 peer-
reviewed articles. Finally, one article was added via cit-
ation chasing and one from the library of a reviewer,
resulting in a total of 29 articles.
Given the tendency for the exclusion of grey literature
within systematic reviews [16], as well as the indication
that much of the criticism of TasP occurs outside the
peer-reviewed literature (e.g., selection bias), we decided
the inclusion of grey literature would provide a more ex-
haustive representation of how the ethical discussions
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order to identify relevant grey literature, we used methods
outlined by the The Centre for Reviews and Dissemination
[17]. This included searching various search engines
(e.g., google), databases (e.g., CATIE), and webpages
(e.g., World Health Organization’s webpage), for the above
listed keywords. This search yielded 26 results (12 online
articles, 6 reports, 5 position statements, and 3 power
point presentations). Including only those sources that
explicitly discussed the ethical and implementation issues
of TasP resulted in a final list of 11 online articles, 3 re-
ports, 3 position papers, and 2 power point presentations.
Data extraction and analysis
Co-authors BP and RK screened the search results for
eligibility. Data containing ethical discussions of TasP
advanced within the peer-reviewed and grey literature
were extracted and managed in Microsoft Excel. Tables 1
and 2 list the peer-reviewed articles and the grey litera-
ture (respectively) included in our scoping review. Dur-
ing data extraction and analysis, we focused on
identifying excerpts from the included documents that
pertain to one or more of the following three questions:
(1) What are the dominant moral concerns associated
with the scaling up and implementation of TasP?; (2)
What are the empirical and/or theoretical gaps that are
either implicitly or explicitly revealed within these discus-
sions?; and (3) To what extent is evidence characterized
or used to morally justify or prohibit various public health
practices pertaining to TasP, and where might additional
research and evidence yield benefits in moving these dis-
cussions towards theoretical or dialogical consensus?
Using these questions as a rubric, we were guided by
both deductive and inductive approaches as we employed
techniques from thematic analysis to identify patterns and
themes within the literature [18]. The co-authors adopted
an iterative process throughout the analysis, so that early
data analysis informed our subsequent decisions about
interpreting the materials. Together, we developed inter-
pretations about recurring, converging and contradictory
themes within the data. As the analysis progressed, we
compared and contrasted the emergent themes and identi-
fied the various rhetorical techniques that were employed.
Key concepts within each theme, along with examples
from the literature, are presented below.
Results
Our search resulted in 29 peer-reviewed articles and 19
grey literature sources that were included in data extrac-
tion and literature mapping. Figure 1 presents a modified
version of the PRISMA-style flow diagram to reflect our
inclusions/exclusion processb. Three dominant themes
emerged in our analysis with respect to the ethical ques-
tions pertaining to TasP implementation and scale-up: (a)balancing individual- and population-level interests; (b)
power relations within clinical practice and competing
resource demands within health care systems; (c) effec -
tiveness considerations and socio-structural contexts of
HIV-related experiences within broader implementation
contexts.
Balancing individual- and population-level interests
The ethical implications of initiating individuals on ART
regardless of their CD4 count emerged as the most salient
and contentious question related to the ethical implemen-
tation of TasP [9]. This debate centers on whether or not
it is ethically justifiable to initiate an intervention (ART)
focused on an individual to derive public health benefits,
rather than for the benefit of the individual. Individualistic
frameworks, communitarian and utilitarian frameworks
are used to advance arguments in this debate.
Individualistic (e.g., social libertarian) frameworks tend
to prioritize individual autonomy against a set of com-
munitarian frameworks that emphasize the interests of
the broader population [19]. Applications of individualis-
tic frameworks suggest that scaling up TasP programs
will result in overly coercive testing and treatment re-
gimes that disregard voluntary consent and participation.
Within these arguments, it is suggested that TasP repre-
sents an intervention on individuals that burdens indi-
viduals in order to promote public health [9], thereby
violating principles of beneficence, non-maleficence and
autonomy – hallmarks of applied medical ethics [20].
For example, the early initiation of ART is largely posi-
tioned as a negative option for the individual due to the
potential for various side effects, including altered lipids,
reduced bone density and kidney damage [21] as well as
the potential for increased antiretroviral resistance [21].
Thus, these arguments suggest that an individual’s
choice not to commence treatment confers an individual
benefit that outweighs concerns for public beneficence
[21]. Additional arguments that suggest individual au-
tonomy trumps overall beneficence rest on the notion
that the long-terms effects of ART adherence are not yet
fully known. For example, some have suggested that
TasP burdens individuals with chronic disease manage-
ment at an early stage of their disease progression,
thereby altering their capacity for economic productivity
as well as their overall quality of life [22].
Questions about the ethics of early initiation of ART
have also been closely embedded in matters of agency. If
the individual freely chooses to initiate TasP (e.g., they
have a sufficient level of autonomy, the process remains
voluntary, and they are equipped with sufficient infor-
mation to make an informed choice), then TasP meets
the ethical criteria set out within applied medical ethics –
regardless of the potential for individual or population-
level harms/benefits [8,21]. However, the positioning of
Table 1 Peer-reviewed publications included in the scoping study
Primary authors Ethical issues
emphasized
Setting Method*
Bärnighausen T, Salomon JA, Sangrujee N: HIV Treatment as Prevention: Issues in Economic
Evaluation. PLoS Med 2012, 9:e1001263.
A, B, C Worldwide Commentary
Bärnighausen T, Tanser F, Dabis F, Newell M-L: Interventions to improve the performance of
HIV health systems for treatment-as-prevention in sub-Saharan Africa. Current
Opinion in HIV and AIDS 2012, 7: 140–150.
C Sub-Saharan
Africa
Rapid Review
Barr D, Amon JJ, Clayton M: Articulating a rights-based approach to HIV treatment and
prevention interventions. Current HIV research 2011, 9: 396–404.
A, B Worldwide Commentary
Chan R: Biomedical Strategies for Human Immunodeficiency Virus (HIV) Prevention? A
New Paradigm. Ann Acad Med Singapore 2012, 41: 595–601.
A, B, C Worldwide Review
Chang LW, Serwadda D, Quinn TC, Wawer MJ: Combination implementation for HIV prevention:
moving from clinical trial evidence to population-level effects. Lancet Infect Dis 2013, 13:65–76.
C Sub-Saharan
Africa
Review
Chen Y: Treatment-Related Optimistic Beliefs and Risk of HIV Transmission: A Review of
Recent Findings (2009–2012) in an Era of Treatment as Prevention. Curr HIV/AIDS Rep 2012,
10: 79–88.
C Worldwide Review
Cohen T, Corbett EL: Test and treat in HIV: success could depend on rapid detection.
The Lancet 2011, 378: 204–206.
A, B, C Sub-Saharan
Africa
Commentary
Dawson L: The Devil in the Details: Thorough Assessment of Evidence and Ethics Is
Needed in Evaluating New HIV Prevention Methods. Am J Bioethics 2012, 12: 33–34.
A, C Worldwide Commentary
Dennin RH, Lafrenz M, Sinn A, Li L: Dilemma of concepts and strategies for the prevention
of spread of HIV in relation to human behavior, law and human rights. J Zhejiang U 2011,
12: 591–610.
A Worldwide Commentary
Forsyth AD, Valdiserri RO: Reaping the prevention benefits of highly active antiretroviral
treatment. Current Opinion in HIV and AIDS 2012, 7: 111–116.
A, B, C Worldwide Commentary
Garnett GP, Baggaley RF: Treating our way out of the HIV pandemic: could we, would we,
should we? The Lancet 2009, 373: 9–11.
A, C Worldwide Commentary
Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sonnerborg A, Nachega JB: Oral
Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for
Adherence, Drug Resistance, and the Success of HIV Treatment Programs. J Infect Dis 2013,
207: S101–S106.
C International Commentary
Haire BG: Because we can: clashes of perspective over researcher obligation in the failed PrEP trials.
Dev world bioethics 2011, 11: 63–74.
A, B, C Worldwide Commentary
Haire BG, Kaldor J, Jordens CFC: How good is “good enough”? The case for varying standards of
evidence according to need for new interventions in HIV prevention. Am J Bioethics 2012, 12: 21–30.
A, B, C Worldwide Commentary
Krellenstein J, Strub, S: The ethical implications of “treatment as prevention” in the United States.
2012, 16:1–4.
A, C United
States
Commentary
Kulkarni SP, Shah KR, Sarma KV, Mahajan AP: Clinical Uncertainties, Health Service Challenges,
and Ethical Complexities of HIV “Test-and-Treat”: A Systematic Review. Am J Public Health 2013,
103: e14–e23.
A, B, C Worldwide Systematic
Review
Macklin R, Cowan E: Given financial constraints, it would be unethical to divert antiretroviral drugs
from treatment to prevention. Health Aff 2012, 31:1537–1544.
A, B United
States
Commentary
McNairy ML, Cohen M, El-Sadr WM: Antiretroviral Therapy for Prevention Is a Combination Strategy.
Curr HIV/AIDS Rep 2013, 10: 152–8.
B, C Worldwide Commentary
McNairy ML, Howard AA, El-Sadr WM: Antiretroviral Therapy for Prevention of HIV and Tuberculosis:
A Promising Intervention but Not a Panacea. JAIDS 2013, 63: S200–7.
B, C Worldwide Commentary
Mayer KH: Antiretrovirals for HIV prevention: translating promise into praxis. The Lancet 2011,
378:206–208.
B, C Sub-Saharan
Africa
Commentary
Montaner JS: Treatment as prevention: a double hat-trick. The Lancet 2011, 378:208–209. C Canada Commentary
Nguyen V-K, Bajos N, Dubois-Arber F, O’Malley J, Pirkle CM: Remedicalizing an epidemic: from HIV
treatment as prevention to HIV treatment is prevention. AIDS 2011, 25:291–293.
A, C Worldwide Commentary
Ostmann F, Saenz C: Separate Goals, Converging Priorities: On the Ethics of Treatment as
Prevention. Developing World Bioethics 2013, 13:57–62.
A, B Worldwide Commentary
Singh JA: Antiretroviral resource allocation for HIV prevention. AIDS 2013, 27:863–865. B, C Worldwide Commentary
Small W, Kerr T: HIV Treatment as Prevention and the Role of Applied Social Science Research.
Journal of AIDS & Clinical Research 2013, 02:102e.
B, C Worldwide Commentary
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Cates W: HPTN 052 and the future of HIV treatment and prevention. The Lancet 2011, 378: 224–5. A, B, C Worldwide Correspondence
Lancet Infectious Diseases: Editorial: Treatment as prevention for HIV. The Lancet Infect
Dis 2011, 11:651.
B, C Worldwide Commentary
Vonn M: British Columbia’s ‘seek and treat’ strategy: a cautionary tale on privacy rights
and informed consent for HIV testing. HIV/AIDS Policy & Law Review 2012, 16:1–4.
A, C Canada Commentary
Williams B, Wood R, Dukay V, Delva W, Ginsburg D, Hargrove J, Stander M, Sheneberger R,
Montaner J, Welte A: Treatment as prevention: preparing the way. JIAS 2011, 14:S6.
A, B, C Worldwide Commentary
*Only articles that included methods were considered reviews. Articles without methods were considered commentaries.
A = Balancing individual- and population-level interests.
B = Power relations within clinical practice and competing resource demands within health care systems.
C = Effectiveness considerations and socio-structural contexts of HIV-related experience.
Table 2 Grey literature reviewed in the scoping study, including the source and title
Year Title Document
type
Source
organization
Ethical issues
emphasized
Setting
2013 Mapping pathways: Developing evidence-based, people-centred strategies
for the use of antiretrovirals as prevention
Report Rand Website C Worldwide
2012 Treatment as Prevention: recognising the creative potential of antiretroviral
medications
Online
article
HIV, Science, and
the Social
A, B Worldwide
2013 Reactions to the test-and-treat models Online
article
NAM AIDS MAP A, C Worldwide
2012 Emerging Issues in Today’s HIV Response: Debate 6 Treatment as Prevention Report AIDSTAR-One B, C Worldwide
2013 The Human Rights Issue Online
article
NAM AIDS MAP A, B Worldwide
2010 Treatment as Prevention: Protecting Individual Autonomy Online
article
aidsperspective.net A, B Worldwide
2009 Ethics of ART for HIV Prevention as a Public Health Intervention Presentation WHO A, B, C Worldwide
2009 Consultation on Antiretroviral Treatment for Prevention of HIV Transmission:
Meeting Report
Report WHO B, C Worldwide
2013 Changing my mind on treatment as prevention Online
article
Positive Lite A, C Worldwide
2010 Prominent Parisian Activist Weighs in on Treatment as Prevention Online
article
POZ Blogs A Worldwide
2010 Views from the front lines: Treatment as Prevention Online
article
CATIE B, C Canada
2013 Treatment as prevention: Bob Leahy in conversation with James Wilton Online
article
CATIE A, C Canada
2012 Treatment benefits for all? Online
article
CATIE A, B Canada
2009 Antriretroviral treatment for prevention Position
statement
UN AIDS A Worldwide
2012 Controlling the HIV Pandemic with Antiretrovirals: Treatment as Prevention
and Pre-Exposure Prophylaxis - Consensus Statement
Position
statement
IAPAC A, B, C Worldwide
2013 The use of antiretroviral therapy to reduce HIV transmission Position
statement
BHIVA, EAGA C Worldwide
2010 Biomedical Prevention Is Always About Social Justice, Too Online
article
HIV Research
Catalyst Forum
A Worldwide
2010 USPHS guidelines: We need reliable evidence to justify an earlier start of
anti-retroviral therapy
Online
article
aidsperspective.net C Worldwide
2011 Are people living with HIV less likely to pass HIV to others if they are on
treatment? Exploring the use of treatment as prevention
Presentation CATIE A Worldwide
A = Balancing individual- and population-level interests.
B = Power relations within clinical practice and competing resource demands within health care systems.
C = Effectiveness considerations and socio-structural contexts of HIV-related experience.
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Figure 1 Flow-chart of articles included and excluded.
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tors has also been problematized. These arguments reveal
the dependence of truly free choice on a variety of condi-
tions, including whether or not a person will have the cap-
acity to adhere, whether or not there will be a consistent
and ‘never-ending’ supply of ART available [23], and if an
individual will have the opportunity to start ART at a later
date if they choose to decline early initiation [19]. Fi-
nally, the potential for the stigmatization of individuals
or groups who choose not to seek early treatment was
also described as an important ethical consideration re-
garding the successful scaling up of TasP [24,25].
Communitarian and utilitarian framings, on the other
hand, offer a view that more strongly features the potential
for TasP to prevent future cases as a primary consider-
ation, counter-positioning previous HIV prevention ap-
proaches as ‘status quo’ and insufficiently equipped to
decrease the spread of HIV [26]. These ‘greater good’
perspectives are often buttressed in the literature byarguments that turn on the extent to which the individ-
ual who uptakes ART could benefit (or at least not suf-
fer) as the short-term effects of the early initiation of
ART have not been demonstrated to be physically detri-
mental [27]. The view that populations and individuals
may concomitantly benefit from beginning ART with
CD4 counts above the previously defined thresholds for
treatment has also been extended to the psychological
realm (e.g., feeling relief in knowing one is less infectious
and therefore less likely to transmit HIV to partners) [21]
as well as other potential physiological benefits [27]. While
detailed discussions regarding some of the mainstays of
population and public health ethics (e.g., relational frame-
works that emphasize notions of ‘the greater good’) did
not feature as strongly in the literature captured in the
current review, some authors did apply key principles,
such as solidarity, stewardship and compassion, and argue
that these principles ought to be considered in terms of
their relevance to population and public health ethics –
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most vulnerable population sub-groups [28]. Some argu-
ments appear to minimize the potential risks for individ-
uals in the face of potentially large population-level gains.
For example, it has been suggested that the addition of
two to three years of treatment (e.g., before the immune
system becomes compromised) could be considered as in-
significant in the face of what could be decades of future
treatment [27].
Power relations within clinical practice and competing
resource demands within health care systems
The second dominant theme that emerged in the ana-
lysis related to power relations within patient-physician
interactions and health care systems more broadly [9].
For example, some authors have suggested that without
unequivocal evidence pertaining to the early uptake of
ART, doctors will still be faced with the challenge of
providing advice to their patients on courses of action in
a context of uncertainty [29]. Particularly in situations
where the evidence is either contradictory or unavailable
(e.g., issues pertaining to the individual-level benefits of
early uptake of ART), the ethical and effective negoti-
ation of power relations inherent in patient-physician in-
teractions will require a relatively high degree of
sophistication from both parties [25,30]. Thus, the import-
ance of training of health care practitioners to compe-
tently relay evidence about the potential risks of early
uptake of ART was also identified as an important compo-
nent to ensure individuals can make informed decisions.
However, inherent difficulties within the doctor-patient re-
lationship regarding comprehension and translation of
risk information were acknowledged (particularly in light
of limited or conflicting evidence in this area) [31].
Questions also have been raised in the literature
around the prioritization and distribution of limited re-
sources. Indeed, in the context of scarce resources, is-
sues related to TasP have led some to question the
extent to which efforts should be focused on treatment
versus prevention [32]. For example, some authors have
suggested that, given a limited set of resources in HIV
treatment and prevention programs, it is inequitable to
divert resources from treatment to prevention [33] –
particularly in relation to taking ARV treatment re-
sources away from resource-poor settings in order to
advance prevention efforts within high-resource or low-
prevalence settings [34,35]. Still others argued that the
very nature of TasP should be seen as paradigm-shifting
and that the goals of treatment and prevention are
converging rather than conflicting [32]. Moreover, the
unknown issues pertaining to the long-term preventative
effects of TasP have been said to be so significant
that predicting the associated costs and benefits is
not yet possible [22]. Ultimately, the treatment versusprevention debates tend to flow from utilitarian frame-
works which argue for the prevention of the greatest
number of deaths versus deontological frameworks which
argue for ethical rules (e.g., the rule/duty of rescue) and
prioritarian principles (e.g., arguing that those who are
currently sick are worse off than those who will become
sick but are currently healthy) [28,33].
Issues related to the scarcity of HIV prevention and
health promotion resources have also led to a set of ar-
guments around targeting efforts at specific population
sub-groups considered most at-risk for transmitting HIV
for cost-specific reasons [36], though many acknowledge
the ethical complexities associated with deciding how ef-
forts ought to be prioritized during implementation
[37,38]. For example, the literature generally acknowl-
edges that population sub-groups that already face the
highest levels of stigmatization (e.g., people who inject
drugs) are likely the most at risk for HIV acquisition and
transmission [39]. This presents a challenge regarding
the population-level effectiveness of TasP, as stigma also
deters people from accessing regular testing, thereby
delaying the onset of diagnosis and treatment, and
undermining the potential for reduced transmission [40].
As a result, some have called for more research on the
efficacy of TasP in marginalized sub-groups in order to
inform ways to ethically reach people at the earliest
stages of infection (i.e., during the first 6 months) when
their viral loads may be highest [36,40].
Others have suggested that explicit criteria be used in
order to determine who should be prioritized to receive
treatment. In general, children and monogamous sex
partners (those least likely to transmit the virus) are
characterized as low priority groups for TasP, whereas
those who are the most likely to spread HIV should be
high priority (e.g., men who have sex with men in high-
risk settings; people who inject drugs; migrant workers
with multiple concurrent partners) [39]. These argu-
ments are premised on the assumption that treatment is
a finite resource and offering treatment to somebody
who is not sick (e.g., individuals with a CD4 count well
above 350 and not showing symptoms of HIV infection)
may deprive a sick person (e.g., an individual with a
CD4 count well below 200 and experiencing HIV-related
symptoms) of treatment. As a result, the principle of
providing treatment to those individuals who will benefit
the most comes into conflict with principles related to
health maximization in which the HIV negative partner
in a sero-discordant relationship will benefit [34].
TasP is most widely referred to as one strategy within
a set of HIV prevention programs, often referred to as a
continuum, cascade or combination prevention strategy
[1,33,36,40,41]. In addition to TasP, other HIV intervention
strategies within health care systems include voluntary
medical male circumcision, campaigns to increase HIV
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pre- and post-exposure prophylaxis (i.e., PEP and PreP)
[38,40-42]. As a result, the successful and ethical imple-
mentation of TasP relies heavily on the capacity of health
systems to accommodate its introduction. Key questions
identified here concern issues pertaining to testing, effective
linkage to care for those who test positive, retention in care,
initiation of ART and assistance with adherence issues to
attain viral suppression [41]. Given that the successful im-
plementation of TasP requires a large increase in the uptake
of HIV testing, prevention, treatment and support services,
questions have been raised regarding the capacity of some
health systems (which are ultimately embedded within lar-
ger socio-political systems) to introduce TasP in ways that
ensure human rights are protected, HIV-related stigma and
discrimination are reduced (or at least not exacerbated),
and to facilitate a sustained and ethical engagement of the
individuals accessing TasP-related programs over very long
periods of time (e.g., indefinitely) [8,24].
Effectiveness considerations and socio-structural contexts
of HIV-related experiences
The third emergent theme centered on questions related
to the external validity of randomized controlled trials
supporting the role of TasP, leading to concerns about
whether existing trial data is sufficient to justify the
widespread implementation of TasP [20,37,43]. While
some argue that the findings of clinical trials support of-
fering ART to individuals in sero-discordant relation-
ships [6], other evidence has suggested that a large
proportion of new HIV infections do not occur within
stable sero-discordant heterosexual relationships [38].
Thus, questions have emerged as to whether or not the
evidence base warrants the implementation and scale up
of TasP within epidemics that are not defined by vaginal-
penile transmission [36]. Others have suggested that while
the efficacy of TasP in clinical trials settings is acceptable,
effectiveness considerations may render the approach’s
‘real-world’ effectiveness vulnerable to criticisms (e.g., ef-
fect sizes will diminish to non-clinically significant levels
in the face of broader implementation realities) [24,36].
Consequently, some have argued that the ethical evalu-
ation of evidence to policy requires more than data from
clinical trials and that a justification to proceeding to
widespread scale up must also be informed by information
pertaining to the social and economic realities of the im-
plementation contexts [37], including community-based
effectiveness trials that may better account for the hetero-
geneity of experiences for people living with HIV [23].
It also has been postulated that effectiveness studies could
reveal TasP as having unintentional inequity-enhancing
consequences. For example, effectiveness trials might
demonstrate the potential for a skewing of beneficial
impacts among various population sub-groups (e.g.,differential uptake across social strata; variegations in the
number and strength of barriers to access along the social
gradient) [22,44]. Unintended effects on individual-level
behavior were also discussed in the literature, particularly
risk compensation behavior (e.g., “condom migration” ef-
fects) [24,42,45,46]. The potential for risk compensation
has led some to ask how this effect could potentially
undermine or blunt the preventative aspects of TasP, re-
inforcing arguments that point to the necessity of main-
taining and perhaps enhancing current standards of HIV
prevention (e.g., risk-reduction counseling in clinical set-
tings) in TasP implementation and scale-up [46].
The issue of adherence in ‘real world’ settings was
widely discussed in the literature, with many suggesting
that the levels of adherence attained in clinical trials can-
not be attained within most settings globally – particularly
within resource-poor settings that present a set of geo-
graphical and sociocultural challenges [24,44,47,48]. For
example, some have argued that evidence pertaining to
adherence must be contextualized to local settings
[37,41,49], with particular attention focused on the social
vulnerabilities that individuals may experience in their
everyday lives (e.g., unstable housing) [8,24,31,33,44,47,48] .
As such, specific implementation challenges were identified
regarding engaging around TasP with individuals who
already face social, cultural and economic barriers to acces-
sing care [49]. For example, one article described possible
scenarios in which some vulnerable individuals (e.g., people
who inject drugs) may become “ghettoized” in that they
can only live in places that support adherence to treatment
[50]. And, it has been suggested that if the scale up and
implementation of TasP is only partially successful, it
could potentially concentrate future infections within
highly vulnerable populations, thereby raising serious
ethical concerns related to health equity and social just-
ice [19]. Questions also have been raised regarding the
ethical implications of incentivizing HIV testing (e.g.,
monetary compensation), particularly within seek and
treat models targeted to vulnerable population sub-groups
[51]. Finally, some have suggested that TasP approaches
that induce treatment initiation ‘early’ may unintentionally
incur system-wide opportunities for patient non-compliance
with drug regimens, which therefore heightens the risk
of additional drug resistance and limits future drug
treatment options [21].
Given these concerns, the social determinants of health
were often cited as a key priority within the literature. For
example, organizations such as UNAIDS and the World
Health Organization recommend comprehensive ap-
proaches to HIV treatment and prevention that also ac-
knowledge and respond to the underlying and upstream
causes of HIV infection, including gender inequality and
access to health care, employment and housing [49,52]. In
some instances the social determinants of health were
Knight et al. BMC Medical Ethics 2014, 15:54 Page 9 of 13
http://www.biomedcentral.com/1472-6939/15/54positioned against the remedicalization of the HIV epi-
demic through the use of biomedical interventions such
as TasP; these arguments suggest that, without paying
sufficient attention to the underlying causes of vulner-
ability and HIV infection, TasP will have only limited
success [51]. Conversely, TasP is positioned as having
already been grounded in the social and structural di-
mensions of HIV-related experiences. For example, in
some implementation settings, legal and policy barriers
(e.g., the criminalization of HIV; absence of evidence-
based HIV prevention and addiction treatment oppor-
tunities or programs) are positioned as key ‘forces’ that
will contribute to the differential uptake/success of TasP,
thereby exacerbating health inequity – particularly
among already vulnerable population sub-groups (e.g.,
people who inject drugs) [11].
Some of the most impassioned arguments in the litera-
ture related to the socio-structural contexts of HIV-
related experiences, with some authors characterizing
TasP’s commitments to addressing the distal causes of
HIV as rhetoric [8]. For these authors, TasP’s capacity
to be effective requires ongoing commitments to
human rights, including the provision of access to
non-discriminatory services, policies and laws [8]. In
particular, laws that criminalize HIV transmission have
been identified as a significant socio-structural barrier
to the ethical and effective scaling up of TasP, as well
as other HIV-related interventions in which TasP is im-
plicated (e.g., routine HIV testing) [8,42].
Discussion
In the current scoping review, a variety of normative
ethical theories were either implicitly or explicitly used
to ground the arguments advanced in the literature re-
garding the implementation of TasP. Specifically, we ex-
plored three key themes that have important ethical and
implementation implications: (1) Effectiveness consider-
ations and socio-structural contexts of HIV-related ex-
periences; (2) Power relations within clinical practice
and competing resource demands within health care sys-
tems; and (3) Balancing individual- and population-level
interests. While conflicting interests associated with vari-
ous ethical frameworks may not be fully resolvable (e.g.,
utilitarian versus deontological approaches), ongoing dis-
cussion and deliberation in this area will help provide pro-
gress towards a reflective equilibrium in which a degree of
ethical coherence and acceptability is acquired. Below we
outline where priorities for empirical research will advance
these ethical discussions. Based on the results of this scop-
ing review, we identify several areas that hold promise for
informing the ethical implementation and scale up of TasP
and that could benefit from new research (see Table 3 for
an abbreviated list of key recommendations from these
findings).Effectiveness studies that integrate ethical dimensions of
TasP implementation
Many questions about the ethical implementation of
TasP are based on a set of uncertainties surrounding its
scale up beyond efficacy trials. These questions tend to
focus on the potential for unintended effects of TasP on
individuals (e.g., long-term effects on those initiating
early ART) as well as on population subgroups (e.g.,
further stigmatization of people who inject drugs) [11].
Ongoing experimental research such as the START
(Strategic Timing of Antiretroviral Treatment; clinical
trial NCT00867048) will provide important information
related to the individual-level physiological effects of early
ART initiation (e.g., long-term side effects) though these
findings will not be available until at least 2015. Findings
from clinical trials represent an important first step in de-
veloping new and much-needed evidence. Embedding
various research approaches within clinical trials (e.g.,
using a variety of social science research methods, includ-
ing qualitative and ethno-epidemiological approaches) will
bridge some of the knowledge gaps identified in our re-
view by studying the social, economic and political con-
texts that influence the capacity for successfully and
ethically implementing and scaling up TasP.
There also is an urgent need to support new empirical
research that characterizes how interactions between
TasP and its various implementation contexts affect the
health and social well being of individuals as well as
populations. Limited data exist on issues pertaining to
risk compensation behavior and the capacity for non-
adherence or early initiation to lead to drug resistance
(despite many of the ethical arguments being premised
on this concern) [51]. While we acknowledge the chal-
lenges related to studying risk compensation (e.g., ex-
perimental designs in this area are themselves unethical
to undertake) [53,54], research efforts focusing on the
relationship between treatment, adherence and HIV risk
behavior is urgently required in order to advance more
fully informed discussion in this area. Nonetheless,
emerging evidence in this area is showing a strong con-
nection between social and structural influences on
adherence among vulnerable populations, including the
legal context of HIV (e.g., HIV non-disclosure legis-
lation) [55]. Indeed, within the current scoping review,
social vulnerability and economic disadvantage emerged
as a dominant ethical concern. As such, issues pertain-
ing to vulnerability require careful and context-specific
empirical and normative analyses that can extend to
many of the upstream issues often considered outside of
the realm of intervention research methodology (e.g., ran-
domized controlled trials; pharmaceutical research). Adopt-
ing techniques from the realm of science and technology
studies (STS) may help reveal how implementation and
ethical considerations are inextricably linked and embedded
Table 3 Priorities for future research
1 Effectiveness studies that integrate ethical dimensions of TasP implementation: Examining the social, economic and political contexts that
influence the capacity for successfully and ethically implementing and scaling up TasP.
2 Examinations of power relations in clinical interactions: Empirical research examining the conditions that enable patients to make fully
informed decisions about TasP that are free of coercion.
3 TasP as a case study of ‘targeting’: Ongoing empirical and philosophical work should aim to characterize the extent to which TasP differentially
affects population sub-groups.
4 Empirical estimations to inform resource distribution decision-making in the context of natural experiments: Move beyond the ongoing
‘treatment versus prevention’ debate and focus energies on developing new empirical estimations regarding the costs (including opportunity costs)
of scaling up TasP.
5 Public engagement and interdisciplinary science: Use techniques associated with implementation and social science (e.g., fieldwork; interviews;
policy analysis) and moral frameworks from the field of population and public health ethics (e.g., social justice frameworks).
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the connections between knowledge about human biology
and technologies (e.g., TasP) alongside the ‘social’ (e.g., so-
cial contexts) and the ‘ethical’ (e.g., normative theory).
In addition, effectiveness studies offer opportunities to
embrace heterogeneous experiences associated with TasP
implementation as well as the social and structural fac-
tors that shape HIV-related experiences – particularly
among vulnerable and socially disadvantaged population
sub-groups. While clinical trials have provided informa-
tion related to heterosexual sero-discordant couples, add-
itional information related to men who have sex with men
and other vulnerable population sub-groups (e.g., people
who inject drugs) is urgently required in order to advance
these discussions. Highly-controlled clinical trial settings
with primarily homogenous samples do not have sufficient
capacity to detect the diversity of pathways and mecha-
nisms through which TasP might be implemented across
contexts; thus, relying exclusively on information regard-
ing implementation and ethical considerations gleaned
from controlled trials may point us in unrealistically uni-
form future directions. Furthermore, homogenous sam-
ples effectively limit (by default) forms of variability that
are important considerations in ethical implementation,
including behavioural characteristics, cultural and ethnic
traditions and gender norms. Building capacity in effect-
iveness studies also could enhance the likelihood of
undertaking international comparative studies to further
determine the extent to which context-based heterogen-
eity (e.g., different forms of health systems) shape or re-
spond to the ethical and implementation dimensions of
TasP.
Examinations of agency, including agentic practices that
may challenge dominant social norms
Many authors argued that if an individual is fully in-
formed and has the capacity to consent (e.g., is theoret-
ically ‘autonomous’ within clinical interactions) to the
early initiation of TasP, public health practices associated
with TasP are ethically justifiable. However, many ques-
tions arose as to whether all individuals exposed to TasPwill have the capacity to be fully autonomous given the
power relations manifest in many clinical interactions –
particularly among vulnerable or disadvantaged popula-
tion sub-groups. In addition, while the literature reviewed
here does not surface concerns that clinicians might make
a set of idiosyncratic ‘choices’ (e.g., those influenced by
prejudices) about who should or should not be offered
TasP, these concerns have been identified in another
body of literature [56] – that pertaining to the allocation
of ART. The roles that prejudice or discrimination play
in relation to the scaling up of TasP as yet remain un-
clear and merit further study. Empirical research in this
area is needed in order to fully distil the conditions that
provide patients with fully informed decisions that are free
as possible from coercion. For example, drawing on
methods and theories from the field of empirical bioethics,
empirical data can be generated to explore the extent to
which clinical interactions pertaining to TasP are volun-
tary [57]. Based on new evidence, there may be opportun-
ities to either improve the ethical theory or change the
clinical practices in order to attain the demands of speci-
fied ethical principles, particularly when agentic practices
of individuals or groups run counter to dominant social
norms [58].
TasP as a case study of ‘targeting’
Within the realm of public health, there is concern that
features of various targeted public health interventions
(whereby a particular subgroup of population is targeted
for an intervention or enhanced intervention focus) may
exacerbate health inequity [59,60], raising moral con-
cerns regarding their use [61,62]. Targeted interventions
have been critiqued for burdening specific population
subgroups with an intervention, while aiming to benefit
those not explicitly targeted through a dispersion of ben-
efits. TasP represents an important area in which more
research, evidence and philosophical deliberation may
provide some resolution pertaining to the ethical impli-
cations of targeted public health practices. In order to
provide moral guidance in this area, ongoing empirical
and philosophical work should aim to characterize the
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and population sub-groups targeted for TasP.
Empirical estimations to inform resource distribution
decision in the context of evolving natural experiments
Perhaps one of the most salient and complex moral di-
lemmas that arises relates to issues around resource distri-
bution within the context of scarcity and various global
austerity measures. Based on our analysis of the literature
included in the current scoping review, we suggest it
would be productive to move beyond the ongoing ‘treat-
ment versus prevention’ debate and focus energies on de-
veloping new empirical estimations regarding the costs
(including opportunity costs) of scaling up TasP. To make
informed decisions globally and locally about ethical scal-
ing up of TasP, it will be important to understand the de-
gree to which investments in TasP efforts may imply
opportunity costs (or have a multiplier effect) within a
broader comprehensive spectrum of care and more up-
stream prevention.
Public engagement and interdisciplinary science
Within these efforts, interdisciplinary and collaborative
approaches are required to engage in normative assess-
ments of various sets of evidence. Indeed, based on these
finding, techniques associated with implementation and
social science (e.g., fieldwork; interviews; policy analysis)
and moral frameworks from the field of population and
public health ethics (e.g., social justice frameworks) will
play an important role in leveraging the successful and
ethical implementation of TasP. Finally, in order to miti-
gate some of the conflicting arguments in this area, we
suggest the source origins of both the methodological
and philosophical frameworks should be addressed to
the fullest extent possible, along with clear, transparent
rationale with respect to how the empirical and norma-
tive interacted to arrive at a moral conclusion. Indeed,
the evaluation of data in this area should continue to en-
gage in critical approaches, given the inherent difficulty of
transforming complex research findings (e.g., population-
level studies) into moral conclusions [63].
Strengths and limitations
This scoping study was limited in its capacity to reveal all
ethical issues that will arise within this area (e.g., there
could be other publications that were not identified using
our search criteria; additional ethical debates pertaining to
TasP take place ‘outside’ of the peer-reviewed and grey
literature). In addition, articles in languages other than
English were not included. Moreover, this study did not
appraise the quality of ethical arguments (e.g., based on a
logic framework) nor the quality of the evidence base on
which various arguments rest. However, by drawing on
both peer-reviewed and grey literature, our review doesprovide illustrations of some dominant ethical issues that
demand new empirical work that could inform the ethical
implementation and scaling up of TasP.
Conclusions
New research and normative deliberation is required in
order to successfully and ethically treat and prevent HIV
through the inclusion of TasP within HIV continuum of
care models. From an ethical and implementation per-
spective, the process of scaling up TasP should not be
conceptualized or practiced as linear, but rather as a
constant feedback loop in which new evidence con-
stantly informs morally robust practices within and dur-
ing its implementation.
Endnotes
aBefore the use of ART for TasP, the CD4 count (a meas-
ure of white blood cells in units of cells/mm3) at which in-
dividuals were recommended to begin ART was generally
accepted to be at approximately 350 cells/mm3 or less
[64]. Since the initiation of TasP, however, some jurisdic-
tions such as British Columbia, Canada, no longer con-
sider CD4 level thresholds [5,65] with respect to ART
initiation. Currently, the World Health Organization rec-
ommends a CD4 < 500 cells/mm3 [66] and some settings
(e.g., Australia) do not provide funding for treatment or
recommend ART if CD4 count is above specifically de-
fined thresholds (e.g., >500 cells/mm3). In other settings
(e.g., low-resource settings), ART may be altogether un-
available for prevention purposes [67-69].
bWhile there are similarities between the methods as-
sociated with systematic reviews and the methods and
techniques of scoping reviews with respect to ‘mapping’
the extent, range and nature of various substantive areas
(e.g., TasP), there are also important differences (see:
Arksey & O’Malley, 2005; Levac & O’Brien, 2010). As a
result, we have modified the PRISMA flow chart to re-
flect our inclusion/exclusion processes.
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